New COVID-19 vaccine trial targets High-Risk groups
NCT ID NCT07069309
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an updated RNA-based COVID-19 vaccine designed for the 2025-2026 season. It involved 774 participants aged 12 and older, including those 65+ and younger people with health conditions that raise their risk of severe COVID-19. Everyone received one shot, and researchers monitored safety and immune responses over about 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BNT162b2 (2025/2026 updated COVID-19 vaccine)
- What this could lead to
- If successful, this could provide a safe and effective updated vaccine that better protects high-risk individuals against current COVID-19 variants.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The vaccine may not provide strong enough protection against future variants, and side effects like injection site reactions or fatigue are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Accellacare - Wilmington
Wilmington, North Carolina, 28401, United States
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO
Springfield, Missouri, 65802, United States
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center
Springfield, Missouri, 65807, United States
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
-
Charlottesville Medical Research
Charlottesville, Virginia, 22911, United States
-
Clinical Research Consulting
Milford, Connecticut, 06460, United States
-
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania, 19107, United States
-
DM Clinical Research- Cyfair
Houston, Texas, 77065, United States
-
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
-
East-West Medical Research Institute
Honolulu, Hawaii, 96814, United States
-
GW Vaccine Research Unit
Washington D.C., District of Columbia, 20037, United States
-
Indago Research & Health Center, Inc
Hialeah, Florida, 33012, United States
-
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah, 84109, United States
-
J. Lewis Research, Inc. / Foothill Family Clinic South
Salt Lake City, Utah, 84121, United States
-
Kentucky Pediatric/ Adult Research
Bardstown, Kentucky, 40004, United States
-
Palm Springs Community Health Center
Miami Lakes, Florida, 33014, United States
-
Rochester Clinical Research, LLC
Rochester, New York, 14609, United States
-
Senders Pediatrics
South Euclid, Ohio, 44121, United States
-
The GW Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?